A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2018
Price : $35 *
At a glance
- Drugs Axitinib (Primary)
- Indications Carcinoma; Ewing's sarcoma; Hepatoblastoma; Liver cancer; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- 05 Nov 2018 Results published in the Cancer
- 25 Jan 2018 Status changed from active, no longer recruiting to completed.
- 13 Nov 2017 Planned End Date changed from 31 Oct 2017 to 1 Nov 2017.